Prognostic values of four Notch receptor mRNA expression in gastric cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Xiaoyu ^a   Liu, Wentao ^b   Tang, Ding ^c   Xiao, Haijuan ^d   Wu, Zhenfeng ^a   Chen, Che ^a   Yao, Xuequan ^a   Liu, Fukun ^a   Li, Gang ^e  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d SHAANXI UNIVERSITY OF CHINESE MEDICINE   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; NOTCH4 PROTEIN, HUMAN; NOTCH4 RECEPTOR; RNA; TUMOR PROTEIN;

BIOSYNTHESIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; METABOLISM; MORTALITY; PATHOLOGY; STOMACH TUMOR; SURVIVAL RATE; TUMOR CELL LINE;

CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; RECEPTOR, NOTCH1; RECEPTOR, NOTCH4; RNA, MESSENGER; RNA, NEOPLASM; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84976904625     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28044     Document Type: Article

References (62)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
2. Yang, W., Raufi, A., Klempner, S. J. Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations. Biochim Biophys Acta 22, 00048-00041 (2014).
3. Oba, K. et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer 49, 1565-1577 (2013).
4. Cao, Y., DePinho, R. A., Ernst, M., Vousden, K. Cancer research: past, present and future. Nat Rev Cancer 11, 749-754, doi: nrc3138 (2011).
5. Lewis, J. Notch signalling and the control of cell fate choices in vertebrates. Semin Cell Dev Biol 9, 583-589, doi: S1084-9521(98)90266-X (1998).
6. Simpson, P. Developmental genetics. The Notch connection. Nature 375, 736-737, doi: 10.1038/375736a0 [doi] (1995).
7. Katoh, M. Notch signaling in gastrointestinal tract (review). Int J Oncol 30, 247-251 (2007).
8. Kopan, R., Ilagan, M. X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216-233, doi: S0092-8674(09)00382-1 (2009).
9. Miele, L. Notch signaling. Clin Cancer Res 12, 1074-1079, doi: 12/4/1074 (2006).
10. Miele, L., Miao, H., Nickoloff, B. J. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6, 313-323 (2006).
11. Alketbi, A., Attoub, S. Notch Signaling in Cancer: Rationale and Strategies for Targeting. Curr Cancer Drug Targets 15, 364-374, doi: CCDT-EPUB-68718 (2015).
12. Chiaramonte, R. et al. Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1alpha chemokine system. Int J Biochem Cell Biol 66, 134-140, doi: S1357-2725(15)00200-9 (2015).
13. Demitrack, E. S. et al. Notch signaling regulates gastric antral LGR5 stem cell function. EMBO J 34, 2522-2536, doi: embj.201490583 (2015).
14. Kim, S. J. et al. Activation of nuclear PTEN by inhibition of Notch signaling induces G2/M cell cycle arrest in gastric cancer. Oncogene 30, 80, doi: onc201580 (2015).
15. Yang, G., Gong, Y., Wang, Q., Wang, Y., Zhang, X. The role of miR-100-mediated Notch pathway in apoptosis of gastric tumor cells. Cell Signal 27, 1087-1101, doi: S0898-6568(15)00059-5 (2015).
16. Yang, Z. et al. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget 6, 5072-5087, doi: 3241 (2015).
17. Yao, J., Qian, C. Over-activated Notch-1 protects gastric carcinoma BGC-823 cells from TNFalpha-induced apoptosis. Dig Liver Dis 41, 867-874, doi: S1590-8658(09)00147-9 (2009).
18. Yan, B. et al. Xiaotan Sanjie decoction attenuates tumor angiogenesis by manipulating Notch-1-regulated proliferation of gastric cancer stem-like cells. World J Gastroenterol 20, 13105-13118, doi: 10.3748/wjg.v20.i36.13105 (2014).
19. Gyorffy, B., Surowiak, P., Budczies, J., Lanczky, A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. Plos one 8, e82241, doi: 10.1371/journal.pone.0082241 (2013).
20. You, Q., Guo, H., Xu, D. Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer. Drug Des Devel Ther 9, 5087-5097, doi: 10.2147/DDDT.S87197 (2015).
21. Dotsch, M. M. et al. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome. Epigenetics 10, 903-912, doi: 10.1080/15592294.2015.1078049 (2015).
22. Ortega, C. E., Seidner, Y., Dominguez, I. Mining CK2 in cancer. Plos one 9, e115609, doi: 10.1371/journal.pone.0115609 (2014).
23. Liu, M., Wang, G., Gomez-Fernandez, C. R., Guo, S. GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer. Plos one 7, e46410 (2012).
24. Tilghman, S. L. et al. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics 12, 2440-2455, doi: M112.023861 (2013).
25. Zhou, C. et al. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res 14, R45, doi: bcr3144 (2012).
26. Maciejczyk, A. et al. Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. J Histochem Cytochem 61, 330-339, doi: 0022155413480148 (2013).
27. Maciejczyk, A. et al. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients. Histol Histopathol 28, 513-524, doi: HH-11-254 (2013).
28. Maciejczyk, A. et al. ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome. Pathol Oncol Res 18, 331-342, doi: 10.1007/s12253-011-9449-9 (2012).
29. Adam, M. A. New prognostic factors in breast cancer. Adv Clin Exp Med 22, 5-15 (2013).
30. Ivanova, L. et al. Prognostic relevance of carbonic anhydrase IX expression is distinct in various subtypes of breast cancer and its silencing suppresses self-renewal capacity of breast cancer cells. Cancer Chemother Pharmacol 75, 235-246, doi: 10.1007/s00280-014-2635-1 (2015).
31. Wu, S. et al. Distinct prognostic values of ALDH1 isoenzymes in breast cancer. Tumour Biol 13, 13, doi: 10.1007/s13277-014-2852-6 (2015).
32. Hong, C. Q. et al. Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study. BMC Cancer 15, 548, doi: 10.1186/s12885-015-1569-2 (2015).
33. Kamieniak, M. M. et al. Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients. Mol Oncol 9, 422-436, doi: S1574-7891(14)00234-8 (2015).
34. Gayarre, J. et al. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. J Gynecol Oncol 12, 12, doi: 26.e36 (2015).
35. Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123, 725-731, doi: 10.1007/s10549-009-0674-9 (2010).
36. Gyorffy, B., Lanczky, A., Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 19, 197-208, doi: ERC-11-0329 (2012).
37. Chen, D. H., Yu, J. W., Jiang, B. J. Contactin 1: A potential therapeutic target and biomarker in gastric cancer. World J Gastroenterol 21, 9707-9716, doi: 10.3748/wjg.v21.i33.9707 (2015).
38. Han, M. E., Oh, S. O. Gastric stem cells and gastric cancer stem cells. Anat Cell Biol 46, 8-18, doi: 10.5115/acb.2013.46.1.8 (2013).
39. Piazzi, G., Bazzoli, F., Ricciardiello, L. Epigenetic silencing of Notch signaling in gastrointestinal cancers. Cell Cycle 11, 4323-4327, doi: 22388 (2012).
40. Wei, G. et al. Notch1 silencing inhibits proliferation and invasion in SGC7901 gastric cancer cells. Mol Med Rep 9, 1153-1158, doi: 10.3892/mmr.2014.1920 (2014).
41. Li, L. C., Peng, Y., Liu, Y. M., Wang, L. L., Wu, X. L. Gastric cancer cell growth and epithelial-mesenchymal transition are inhibited by gamma-secretase inhibitor DAPT. Oncol Lett 7, 2160-2164, doi: 10.3892/ol.2014.1980 (2014).
42. Luo, D. H. et al. Differential expression of Notch1 intracellular domain and p21 proteins, and their clinical significance in gastric cancer. Oncol Lett 7, 471-478, doi: 10.3892/ol.2013.1751 (2014).
43. Du, X. et al. Role of Notch signaling pathway in gastric cancer: a meta-analysis of the literature. World J Gastroenterol 20, 9191-9199, doi: 10.3748/wjg.v20.i27.9191 (2014).
44. Bauer, L. et al. Clinical Significance of NOTCH1 and NOTCH2 Expression in Gastric Carcinomas: An Immunohistochemical Study. Front Oncol 5, 94, doi: 10.3389/fonc.2015.00094 (2015).
45. Sun, Y. et al. Differential Notch1 and Notch2 expression and frequent activation of Notch signaling in gastric cancers. Arch Pathol Lab Med 135, 451-458, doi: 10.1043/2009-0665-OA.1 (2011).
46. Tseng, Y. C. et al. Notch2-induced COX-2 expression enhancing gastric cancer progression. Mol Carcinog 51, 939-951, doi: 10.1002/mc.20865 (2012).
47. Bauer, L. et al. Expression profiling of stem cell-related genes in neoadjuvant-treated gastric cancer: a NOTCH2, GSK3B and betacatenin gene signature predicts survival. Plos one 7, e44566, doi: 10.1371/journal.pone.0044566 (2012).
48. Kang, H. et al. Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression. Histopathology 61, 576-586, doi: 10.1111/j.1365-2559.2012.04274.x (2012).
49. Qian, C. et al. Notch4 promotes gastric cancer growth through activation of Wnt1/beta-catenin signaling. Mol Cell Biochem 401, 165-174, doi: 10.1007/s11010-014-2304-z (2015).
50. Anastas, J. N., Moon, R. T. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13, 11-26, doi: nrc3419 (2013).
51. You, L. et al. Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect 19, 27-31, doi: 965871 (2006).
52. McCrea, P. D., Gottardi, C. J. Beyond beta-catenin: prospects for a larger catenin network in the nucleus. Nat Rev Mol Cell Biol 17, 55-64, doi: nrm.2015.3 (2016).
53. Chiurillo, M. A. Role of the Wnt/beta-catenin pathway in gastric cancer: An in-depth literature review. World J Exp Med 5, 84-102, doi: 10.5493/wjem.v5.i2.84 (2015).
54. Casimiro, M. C., Velasco-Velazquez, M., Aguirre-Alvarado, C., Pestell, R. G. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin Investig Drugs 23, 295-304, doi: 10.1517/13543784.2014.867017 (2014).
55. Feakins, R. M., Nickols, C. D., Bidd, H., Walton, S. J. Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol 34, 1276-1282, doi: S0046817703004726 (2003).
56. Pradeep, A. et al. Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells. Oncogene 23, 3689-3699, doi: 10.1038/sj.onc.1207454 (2004).
57. Tai, W., Mahato, R., Cheng, K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release, doi: S0168-3659(10)00263-4 (2010).
58. Tzahar, E., Yarden, Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1377, M25-37, doi: S0304-419X(97)00032-2 (1998).
59. Ruschoff, J. et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 25, 637-650, doi: modpathol2011198 (2012).
60. Rajagopal, I., Niveditha, S. R., Sahadev, R., Nagappa, P. K., Rajendra, S. G. HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas. J Clin Diagn Res 9, EC06-10, doi: 10.7860/JCDR/2015/12581.5630 (2015).
61. Yao, J. et al. Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/beta-catenin. Cancer Biol Ther 14, 833-839, doi: 25332 (2013).
62. Hong, K. J., Wu, D. C., Cheng, K. H., Chen, L. T., Hung, W. C. RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation. J Cell Physiol 229, 191-201, doi: 10.1002/jcp.24434 (2014).